Literature DB >> 20388657

Congenital malaria due to chloroquine-resistant Plasmodium vivax: a case report.

Kriti Mohan1, M M Maithani.   

Abstract

The clinical manifestation of malaria in neonates and young infants is non-specific and differs from that of adults and older children. So a high index of suspicion is needed to diagnose malaria in early infancy. Chloroquine is the first-line treatment for Plasmodium vivax malaria in most parts of the world. This case report details a case of chloroquine-resistant malaria due to P. vivax by transplacental transmission from mother with mixed infection of P. falciparum and P. vivax in a 26-day-old young infant who presented with moderate grade fever and reviews the literature of malaria in infantile and neonatal age groups. And we concluded that high suspicion of malaria is needed to diagnose congenital malaria. Primigravida women with placental malaria pose high risk for congenital infection in baby and emerging chloroquine-resistant P. vivax in congenital malaria.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20388657     DOI： 10.1093/tropej/fmq025

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN： 0142-6338            Impact factor:   1.165


  8 in total

Review 1.  The Biology of Plasmodium vivax.

Authors:  John H Adams; Ivo Mueller
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 2.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981

3.  Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.

Authors:  Vahideh Valizadeh; Sedigheh Zakeri; Akram A Mehrizi; Sedigheh Mirkazemi; Navid D Djadid
Journal:  Med Microbiol Immunol       Date:  2015-08-05       Impact factor: 3.402

4.  Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a.

Authors:  Francis B Ntumngia; Richard Thomson-Luque; Sandra Galusic; Gabriel Frato; Sarah Frischmann; David S Peabody; Bryce Chackerian; Marcelo U Ferreira; Christopher L King; John H Adams
Journal:  J Infect Dis       Date:  2018-08-24       Impact factor: 5.226

Review 5.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

6.  An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies.

Authors:  Francis B Ntumngia; Camilla V Pires; Samantha J Barnes; Miriam T George; Richard Thomson-Luque; Flora S Kano; Jessica R S Alves; Darya Urusova; Dhelio B Pereira; Niraj H Tolia; Christopher L King; Luzia H Carvalho; John H Adams
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

7.  The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects.

Authors:  Francis B Ntumngia; Richard Thomson-Luque; Camilla V Pires; John H Adams
Journal:  J Receptor Ligand Channel Res       Date:  2016-09-26

8.  Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan.

Authors:  Mohammad Rafiul Hoque; Mohammed Mohieldien Abbas Elfaki; Md Atique Ahmed; Seong-Kyun Lee; Fauzi Muh; Musab M Ali Albsheer; Muzamil Mahdi Abdel Hamid; Eun-Taek Han
Journal:  Malar J       Date:  2018-08-17       Impact factor: 2.979
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.